Detalhe da pesquisa
1.
Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αß+ T cells targeting multiple myeloma.
Blood
; 143(10): 895-911, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890146
2.
ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma.
Blood
; 143(11): 996-1005, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37992230
3.
RAS/RAFlandscape in monoclonal plasma cell conditions.
Blood
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643494
4.
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
Blood
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551812
5.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660812
6.
Single-cell profiling in multiple myeloma: insights, problems, and promises.
Blood
; 142(4): 313-324, 2023 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37196627
7.
The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.
Blood
; 141(13): 1574-1583, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35984902
8.
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
Blood
; 141(6): 620-633, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36223594
9.
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Blood
; 141(21): 2599-2614, 2023 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630605
10.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Blood
; 141(14): 1724-1736, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36603186
11.
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
Blood
; 141(23): 2841-2852, 2023 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877894
12.
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth.
Blood
; 141(4): 391-405, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36126301
13.
Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma.
Gastroenterology
; 165(2): 357-373, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37178737
14.
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.
Blood
; 138(20): 1980-1985, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34792571
15.
miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.
Blood
; 137(14): 1905-1919, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33751108
16.
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
Blood
; 136(20): 2334-2345, 2020 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32844992
17.
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Blood
; 136(26): 3033-3040, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33367546
18.
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.
Blood
; 136(4): 468-479, 2020 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32187357
19.
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment.
Haematologica
; 107(6): 1410-1426, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670358
20.
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.
Haematologica
; 107(8): 1891-1901, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045690